Protalix BioTherapeutics annual capital expenditures (capex)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Protalix BioTherapeutics Capital Expenditures (CapEx) Growth & History (PLX)
Protalix BioTherapeutics's capital expenditures (capex) was $1.6M for fiscal 2025.
View full Protalix BioTherapeutics company overviewProtalix BioTherapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.6M | $356,000 | +27.77% |
| 2024 | 2024-12-31 | $1.3M | $133,000 | +11.58% |
| 2023 | 2023-12-31 | $1.1M | $521,000 | +82.96% |
| 2022 | 2022-12-31 | $628,000 | −$831,000 | −56.96% |
| 2021 | 2021-12-31 | $1.5M | $804,000 | +122.75% |
| 2020 | 2020-12-31 | $655,000 | $28,000 | +4.47% |
| 2019 | 2019-12-31 | $627,000 | −$59,000 | −8.60% |
| 2018 | 2018-12-31 | $686,000 | −$285,000 | −29.35% |
| 2017 | 2017-12-31 | $971,000 | $122,000 | +14.37% |
| 2016 | 2016-12-31 | $849,000 | $385,000 | +82.97% |
| 2015 | 2015-12-31 | $464,000 | −$321,000 | −40.89% |
| 2014 | 2014-12-31 | $785,000 | −$1.1M | −58.47% |
| 2013 | 2013-12-31 | $1.9M | −$178,000 | −8.61% |
| 2012 | 2012-12-31 | $2.1M | −$3.6M | −63.75% |
| 2011 | 2011-12-31 | $5.7M | −$2.1M | −27.37% |
| 2010 | 2010-12-31 | $7.9M | $1.7M | +26.80% |
| 2009 | 2009-12-31 | $6.2M | — | — |
Protalix BioTherapeutics quarterly capital expenditures (capex)
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $593,000 | $162,000 | +37.59% |
| Q1 2026 | 2026-03-31 | $761,000 | $455,000 | +148.69% |
| Q4 2025 | 2025-12-31 | $403,000 | −$22,000 | −5.18% |
| Q3 2025 | 2025-09-30 | $498,000 | $411,000 | +472.41% |
| Q2 2025 | 2025-06-30 | $431,000 | $259,000 | +150.58% |
| Q1 2025 | 2025-03-31 | $306,000 | −$292,000 | −48.83% |
| Q4 2024 | 2024-12-31 | $425,000 | $175,000 | +70.00% |
| Q3 2024 | 2024-09-30 | $87,000 | −$360,000 | −80.54% |
| Q2 2024 | 2024-06-30 | $172,000 | −$32,000 | −15.69% |
| Q1 2024 | 2024-03-31 | $598,000 | $350,000 | +141.13% |
| Q4 2023 | 2023-12-31 | $250,000 | $37,000 | +17.37% |
| Q3 2023 | 2023-09-30 | $447,000 | $389,000 | +670.69% |
| Q2 2023 | 2023-06-30 | $204,000 | $76,000 | +59.38% |
| Q1 2023 | 2023-03-31 | $248,000 | $19,000 | +8.30% |
| Q4 2022 | 2022-12-31 | $213,000 | −$235,000 | −52.46% |
| Q3 2022 | 2022-09-30 | $58,000 | −$286,000 | −83.14% |
| Q2 2022 | 2022-06-30 | $128,000 | −$153,000 | −54.45% |
| Q1 2022 | 2022-03-31 | $229,000 | −$157,000 | −40.67% |
| Q4 2021 | 2021-12-31 | $448,000 | $173,000 | +62.91% |
| Q3 2021 | 2021-09-30 | $344,000 | $242,000 | +237.25% |
| Q2 2021 | 2021-06-30 | $281,000 | $69,000 | +32.55% |
| Q1 2021 | 2021-03-31 | $386,000 | $320,000 | +484.85% |
| Q4 2020 | 2020-12-31 | $275,000 | $247,000 | +882.14% |
| Q3 2020 | 2020-09-30 | $102,000 | −$290,000 | −73.98% |
| Q2 2020 | 2020-06-30 | $212,000 | $175,000 | +472.97% |
| Q1 2020 | 2020-03-31 | $66,000 | −$104,000 | −61.18% |
| Q4 2019 | 2019-12-31 | $28,000 | −$160,000 | −85.11% |
| Q3 2019 | 2019-09-30 | $392,000 | $288,000 | +276.92% |
| Q2 2019 | 2019-06-30 | $37,000 | −$108,000 | −74.48% |
| Q1 2019 | 2019-03-31 | $170,000 | −$79,000 | −31.73% |
| Q4 2018 | 2018-12-31 | $188,000 | −$102,000 | −35.17% |
| Q3 2018 | 2018-09-30 | $104,000 | −$34,000 | −24.64% |
| Q2 2018 | 2018-06-30 | $145,000 | −$178,000 | −55.11% |
| Q1 2018 | 2018-03-31 | $249,000 | $29,000 | +13.18% |
| Q4 2017 | 2017-12-31 | $290,000 | $173,000 | +147.86% |
| Q3 2017 | 2017-09-30 | $138,000 | −$19,000 | −12.10% |
| Q2 2017 | 2017-06-30 | $323,000 | −$1,000 | −0.31% |
| Q1 2017 | 2017-03-31 | $220,000 | −$31,000 | −12.35% |
| Q4 2016 | 2016-12-31 | $117,000 | $113,000 | +2825.00% |
| Q3 2016 | 2016-09-30 | $157,000 | $29,000 | +22.66% |
| Q2 2016 | 2016-06-30 | $324,000 | $91,000 | +39.06% |
| Q1 2016 | 2016-03-31 | $251,000 | $152,000 | +153.54% |
| Q4 2015 | 2015-12-31 | $4,000 | −$164,000 | −97.62% |
| Q3 2015 | 2015-09-30 | $128,000 | −$118,000 | −47.97% |
| Q2 2015 | 2015-06-30 | $233,000 | $125,000 | +115.74% |
| Q1 2015 | 2015-03-31 | $99,000 | −$164,000 | −62.36% |
| Q4 2014 | 2014-12-31 | $168,000 | −$54,000 | −24.32% |
| Q3 2014 | 2014-09-30 | $246,000 | −$81,000 | −24.77% |
| Q2 2014 | 2014-06-30 | $108,000 | −$591,000 | −84.55% |
| Q1 2014 | 2014-03-31 | $263,000 | −$379,000 | −59.03% |
| Q4 2013 | 2013-12-31 | $222,000 | −$29,000 | −11.55% |
| Q3 2013 | 2013-09-30 | $327,000 | −$443,000 | −57.53% |
| Q2 2013 | 2013-06-30 | $699,000 | $462,000 | +194.94% |
| Q1 2013 | 2013-03-31 | $642,000 | −$168,000 | −20.74% |
| Q4 2012 | 2012-12-31 | $251,000 | −$453,000 | −64.35% |
| Q3 2012 | 2012-09-30 | $770,000 | −$215,000 | −21.83% |
| Q2 2012 | 2012-06-30 | $237,000 | −$1.2M | −83.22% |
| Q1 2012 | 2012-03-31 | $810,000 | −$1.8M | −68.89% |
| Q4 2011 | 2011-12-31 | $704,000 | — | — |
| Q3 2011 | 2011-09-30 | $985,000 | −$358,000 | −26.66% |
| Q2 2011 | 2011-06-30 | $1.4M | — | — |
| Q1 2011 | 2011-03-31 | $2.6M | — | — |
| Q3 2010 | 2010-09-30 | $1.3M | — | — |
Protalix BioTherapeutics capital expenditures (capex) trends
Over the last five fiscal years, Protalix BioTherapeutics's capital expenditures (capex) increased from $655,000 to $1.6M, a change of $983,000. The latest reported quarter, Q2 2026, shows $593,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protalix BioTherapeutics source filings ↗